CA2304720A1 - Apolipoprotein e/growth factor complexes and methods of use - Google Patents

Apolipoprotein e/growth factor complexes and methods of use Download PDF

Info

Publication number
CA2304720A1
CA2304720A1 CA002304720A CA2304720A CA2304720A1 CA 2304720 A1 CA2304720 A1 CA 2304720A1 CA 002304720 A CA002304720 A CA 002304720A CA 2304720 A CA2304720 A CA 2304720A CA 2304720 A1 CA2304720 A1 CA 2304720A1
Authority
CA
Canada
Prior art keywords
apolipoprotein
complex
composition
apoe
ngf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002304720A
Other languages
English (en)
French (fr)
Inventor
William D. Matthew
Warren J. Strittmatter
Catherine R. Gutman
Stephanie M. Fullerton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2304720A1 publication Critical patent/CA2304720A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002304720A 1997-09-30 1998-09-29 Apolipoprotein e/growth factor complexes and methods of use Abandoned CA2304720A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6053397P 1997-09-30 1997-09-30
US60/060,533 1997-09-30
PCT/US1998/020591 WO1999016460A2 (en) 1997-09-30 1998-09-29 Apolipoprotein e/growth factor complexes and methods of use

Publications (1)

Publication Number Publication Date
CA2304720A1 true CA2304720A1 (en) 1999-04-08

Family

ID=22030099

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002304720A Abandoned CA2304720A1 (en) 1997-09-30 1998-09-29 Apolipoprotein e/growth factor complexes and methods of use

Country Status (5)

Country Link
EP (1) EP1019081A2 (de)
JP (1) JP2001518449A (de)
AU (1) AU9676598A (de)
CA (1) CA2304720A1 (de)
WO (1) WO1999016460A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2002072144A1 (fr) * 2001-03-12 2002-09-19 Institute Of Gene And Brain Science Remedes pour lesions nerveuses
GB0329254D0 (en) * 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
EP1988920A1 (de) 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Verfahren zur behandlung von fettsucht durch verabreichung eines trkb-antagonisten
WO2017165515A1 (en) * 2016-03-23 2017-09-28 The Research Institute At Nationwide Children's Hospital Stimulation of bone growth using apolipoprotein e

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
EP0731108A1 (de) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Verfahren zur Herstellung eines Heilmittels zur Oligodendrozyten-Regenerierung

Also Published As

Publication number Publication date
WO1999016460A3 (en) 1999-06-17
JP2001518449A (ja) 2001-10-16
AU9676598A (en) 1999-04-23
EP1019081A2 (de) 2000-07-19
WO1999016460A2 (en) 1999-04-08

Similar Documents

Publication Publication Date Title
Hamilton et al. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin
US6472178B1 (en) Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
Pasquin et al. Ciliary neurotrophic factor (CNTF): New facets of an old molecule for treating neurodegenerative and metabolic syndrome pathologies
US9605073B2 (en) Modulation of activity of neurotrophins
Fischer et al. Reversal of spatial memory impairments in aged rats by nerve growth factor and neurotrophins 3 and 4/5 but not by brain-derived neurotrophic factor.
US6680295B1 (en) Method and pharmaceutical composition for prevention and treatment of brain damage
ES2211991T3 (es) Formulacion estabilizante para el ngf.
WO1996009064A1 (en) Method and pharmaceutical composition for prevention and treatment of brain damage
US6313089B1 (en) Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
EA039314B1 (ru) Фармацевтически приемлемые соли полипептидов и их применение
CA2304720A1 (en) Apolipoprotein e/growth factor complexes and methods of use
EP0593516B1 (de) Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie
US6143714A (en) Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
US6410510B1 (en) Administration modified ciliary neurotrophic factors
US7951359B2 (en) Compositions and methods for therapy or prevention of chemotherapy-induced neuropathy
US6964947B1 (en) Stabilizing formulation for NGF
US20110274647A1 (en) IL6R/IL6 Chimera for Therapy of Chemotherapy-Induced Peripheral Neuropathy
JP2003507393A (ja) 改変された毛様体神経栄養因子、それらを作製する方法およびそれらの使用方法
US20090291887A1 (en) Proteins of the SDF-1-Family for the Manufacturing of a Medicament
Sieber Selective neurotrophic support of ventral mesencephalic dopamine neurons by local type 1 astrocytes
DE10317369A1 (de) proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen
WO2000033864A1 (fr) Remedes contre les defaillances tactiles

Legal Events

Date Code Title Description
FZDE Discontinued